“ Mirvaso Gel is an important breakthrough to address the unmet need of treating the persistent facial redness of rosacea,” said Mark Jackson, M.D., Clinical Professor of Medicine at the University of ...

Mirvaso (brimonidine; Galderma) Topical Gel 0.33% is now available in a pump dispenser. Galderma announced the availability of Mirvaso (brimonidine) Topical Gel 0.33% in a new pump delivery system, ...

Galderma Laboratories recently announced that a new pump dispenser design for Mirvaso topical gel, 0.33% is available to treat persistent erythema associated with rosacea in adults. Mirvaso ...

MIRVASO (brimonidine) 0.33% Topical Gel The FDA has approved Galderma's Mirvaso (brimonidine) topical gel for the topical treatment of the facial erythema associated with rosacea in adults 18 years or ...

- Galderma portfolio expands to offer a fast onset and long-acting alpha-2 adrenergic receptor agonist - Galderma, a leading global pharmaceutical company exclusively focused on dermatology, today ...

FORT WORTH, Texas--(BUSINESS WIRE)--Galderma Laboratories, L.P., a global leader focused on medical treatment options in dermatology and skin health and the maker of Cetaphil®, today announced the ...

NEW YORK (CBSNewYork) --Do you blush easily or often have red, rosy cheeks? You may have a skin condition call rosacea. The Food & Drug Administration has approved a new gel to treat the embarrassing ...

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended marketing of brimonidine tartrate 3 mg/g topical gel (Mirvaso, Galderma) for the symptomatic ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved brimonidine topical gel, 0.33% for treatment of facial erythema of adults with rosacea, ...

FORT WORTH, Texas — The Food and Drug Administration has approved a drug made by Galderma Labs for treating a side effect of rosacea in adults, the company said. Galderma announced the approval of ...

Rosacea is a chronic relapsing disease of the facial skin, characterised by recurrent episodes of facial flushing, persistent erythema, telangiectasia (fine, dilated blood vessels), papules and ...

Tentative approval means that the marketing application sufficiently demonstrated the safety and efficacy of the product, but pending litigation (usually patent-related) has yet to be resolved.